• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 28, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Highly effective cervical cancer screening for low-income countries

Bioengineer by Bioengineer
March 1, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Taking a small sample of cells from women at high-risk of cervical cancer could be a cost-effective and accurate strategy for early diagnosis in low and middle income countries (LMICs), according to research led by Queen Mary University of London (QMUL), funded by Cancer Research UK and published in the Journal of Global Oncology.

Cervical cancer is the second most common cancer in women in developing countries, and globally some quarter of a million women die from the disease each year – most of them from LMICs.

To reduce the incidence of cervical cancer in developed countries, nationwide screening is offered to all women. Taking a small cluster of cells ('cytology') to diagnose disease before it progresses to cancer has been extremely effective. But in less developed countries, a lack of infrastructure and quality management have hampered widespread implementation of effective screening programmes.

In the first study to evaluate the use of cytology to diagnose cervical cancer in LMICs, the researchers looked at cytology results from 717 cervical cancers from 23 studies in countries including India, Bangladesh, China, Thailand, Kenya, South Africa, Uganda, Peru, El Salvador, Costa Rica, Nicaragua, Brazil, Argentina and Egypt. They argued that cytology in these countries might be used to diagnose cervical cancer earlier.

The researchers found that even in these low-resource settings, cytology was very sensitive and consistent for detecting invasive cancer. Cytology was found to successfully find cancer with 95.9 per cent accuracy in high-risk women showing symptoms.

Corresponding author Dr Alejandra Castanon from QMUL said: "Cytology has long been established as an excellent screening tool to prevent cervical cancer by detecting precancerous lesions. However, little research has been carried out regarding its sensitivity to cancer.

"We've found that this is an excellent tool for targeted screening of populations at high risk of cervical cancer, leading to early diagnosis. In resource-poor settings with limited facilities to treat advanced cancers, this could have a big impact on cervical cancer mortality."

The researchers say that restricting cytology to symptomatic women and referring only those with severe lesions would lead to substantially fewer women requiring further investigation. This could mean a reduction in burden on resource and cost, and could result in the diagnosis of cervical cancers at an earlier stage to improve overall survival from the disease.

Co-author Professor Peter Sasieni from QMUL added: "The implications are that, even when a country lacks infrastructure to implement a quality-assured cervical screening programme nationally, it might be able to facilitate early diagnosis of cervical cancer by using cervical cytology, and only referring women with severely abnormal smears."

###

For more information, please contact:

Joel Winston, Public Relations Manager
Queen Mary University of London
[email protected]
Tel: +44-0-207-882-7943 / +44-0-7970-096-188

Notes to the editor

Research paper: 'Systematic review and meta-analysis of individual patient data assessing the sensitivity of cervical cytology for diagnosing cervical cancer in low and middle income countries'. Alejandra Castanon, Rebecca Landy, Dimitrios Michalopoulos, Roshni Bhudia, Hannah Leaver, You Lin Qiao, Fanghui Zhao, Peter Sasieni. Journal of Global Oncology 2017.

About Queen Mary University of London

Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 23,120 students from more than 155 countries.

A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014).

As well as our main site at Mile End — which is home to one of the largest self-contained residential campuses in London – we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields.

We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End.

Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research.

QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.

Media Contact

Joel Winston
[email protected]
44-020-788-27943
@QMUL

http://www.qmul.ac.uk

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Turbulent Flow in Heavily Polluted Tijuana River Elevates Regional Air Quality Risks

August 28, 2025

New CEA-Based Surveillance Boosts Gastric Cancer

August 28, 2025

Zharp1-163: Dual Inhibitor Tackles Inflammation, Kidney Injury

August 28, 2025

Enhancing Pediatric Nursing Education with Advanced Simulators

August 28, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Turbulent Flow in Heavily Polluted Tijuana River Elevates Regional Air Quality Risks

New CEA-Based Surveillance Boosts Gastric Cancer

Zharp1-163: Dual Inhibitor Tackles Inflammation, Kidney Injury

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.